✦ LIBER ✦

ST1571: a paradigm for clinical trials of molecularly targeted agents

✍ Scribed by B.J Druker

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

363 Dose of the molecularly targeted age

✍ S. Gupta; A. Alqwasmi; S. Hunsberger; L. Rubinstein; P. Ivy; R. Royds; P. LoRuss 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB

The Clinical Development of Molecularly

✍ Ozlem U. Ataman; Sally J. Sambrook; Chris Wilks; Andrew Lloyd; Amanda E. Taylor; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 642 KB

Heterogeneity in the definition of dose-

✍ Christophe Le Tourneau; Albiruni R.A. Razak; Hui K. Gan; Simona Pop; Véronique D 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 159 KB

449 Increased levels of serum creatine k

✍ V. Moreno Garcia; R. Molife; J. Pedersen; M. Puglisi; M. Blanco; B. Basu; K. Sha 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB

1260 POSTER Preliminary Signs of Efficac

✍ J. Arrondeau; X. Paoletti; S. Pop; P. Tresca; V. Dieras; C. Le Tourneau 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Current challenges for the early clinica

✍ Christophe Le Tourneau; Véronique Diéras; Patricia Tresca; Wulfran Cacheux; Xavi 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 148 KB